Home>>Signaling Pathways>> Neuroscience>> Dopamine Receptor>>Sultopride (LIN-1418)

Sultopride (LIN-1418)

Catalog No.GC31188

Sultopride (LIN-1418) (LIN-1418) is a selective antagonist of dopamine D2 receptor.

Products are for research use only. Not for human use. We do not sell to patients.

Sultopride (LIN-1418) Chemical Structure

Cas No.: 53583-79-2

Size Price Stock Qty
5mg
$110.00
In stock
10mg
$193.00
In stock
25mg
$386.00
In stock
50mg
$644.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Sultopride is a selective antagonist of dopamine D2 receptor.

Sultopride is a selective antagonist of dopamine D2 receptor. DOPAC and HVA levels in the striatum, the nucleus accumbens and the medial prefrontal cortex are higher in the rats treated with Sultopride and sulpiride than those of the controls. In the striatum, DOPAC and HVA levels are higher in the Sultopride-treated rats than the sulpiride-treated rats (p<0.05). In the nucleus accumbens, DOPAC levels are higher in the Sultopride-treated rats than sulpiride treated rats (p<0.05). In the Sultopride-treated rats, DOPAC and HVA levels are higher in the striatum or in the nucleus accumbens than in the medial prefrontal cortex (p<0.05)[1].

[1]. Moriuchi K, et al. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain. Neurochem Res. 1995 Jan;20(1):95-9.

Reviews

Review for Sultopride (LIN-1418)

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Sultopride (LIN-1418)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.